Eisai and Biogen Secure NMPA Acceptance for Subcutaneous LEQEMBI in China

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...

January 07, 2026 | Wednesday | News
MindRank Initiates Pivotal Phase III Trial for AI-Designed Oral GLP-1 Candidate MDR-001

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...

January 07, 2026 | Wednesday | News
WuXi Biologics Achieves ISO 20400 Sustainable Procurement Certification, Strengthening Global Supply Chain Resilience

WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrate...

January 06, 2026 | Tuesday | News
Kelun-Biotech’s TROP2 ADC sac-TMT Combo with Keytruda Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK)  announced that its TROP2-directed antibody-drug ...

January 06, 2026 | Tuesday | News
Samsung Bioepis Reclaims European Commercial Rights for BYOOVIZ®, Expanding Direct Biosimilar Portfolio

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimi...

January 05, 2026 | Monday | News
Mabwell Secures Indonesian Approval for Adalimumab Biosimilar JUNMAIKANG

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its Adalimumab Injection 9MW01...

January 02, 2026 | Friday | News
Valneva Regains Full Rights to Single-Shot Chikungunya Vaccine, Ends Licensing Deal with Serum Institute of India

Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Grou...

January 02, 2026 | Friday | News
Mabwell Doses First Patient in World’s First Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of...

January 01, 2026 | Thursday | News
Transcenta Therapeutics Enters Strategic Bioprocessing Collaboration With EirGenix

  Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-inte...

December 31, 2025 | Wednesday | News
HUTCHMED’s Fanregratinib NDA for Intrahepatic Cholangiocarcinoma Accepted for Priority Review in China

NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...

December 31, 2025 | Wednesday | News
CARsgen Submits Dual IND Applications in China for Allogeneic BCMA CAR-T CT0596 in Multiple Myeloma and Plasma Cell Leukemia

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submi...

December 30, 2025 | Tuesday | News
Harbour BioMed Forms Strategic Alliance With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...

December 30, 2025 | Tuesday | News
Viva Biotech Showcases Integrated PK/PD Platform Across Small Molecules, Peptides, PROTACs, and Antibodies

Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and m...

December 30, 2025 | Tuesday | News
T-MAXIMUM Pharmaceutical Secures FDA IND Clearance for Allogeneic CAR-T MT027 in Recurrent Glioblastoma

T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...

December 29, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close